Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells

Molecular and Cellular Biology

Volumn 25, Issue 7, 2005, Pages 2673-2687

  Poizat, Coralie ^a,d   Puri, Pier Lorenzo ^b,c   Bai, Yan ^a   Kedes, Larry ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BURNHAM INSTITUTE   (United States)

^c DULBECCO TELETHON INSTITUTE   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HISTONE ACETYLTRANSFERASE PCAF; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; HEART MUSCLE CELL; IN VITRO STUDY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RAT;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELLS, CULTURED; DNA-BINDING PROTEINS; DOXORUBICIN; E1A-ASSOCIATED P300 PROTEIN; ENZYME ACTIVATION; GATA4 TRANSCRIPTION FACTOR; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCYTES, CARDIAC; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; THREONINE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15044342095     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.7.2673-2687.2005     Document Type: Article

References (77)

1. Ait-Si-Ali, S., S. Ramirez, F. X. Barre, F. Dkhissi, L. Magnaghi-Jaulin, J. A. Girault, P. Robin, M. Knibiehler, L. L. Pritchard, B. Ducommun, D. Trouche, and A. Harel-Bellan. 1998. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 396:184-186.
2. Arai, M., A. Yoguchi, T. Takizawa, T. Yokoyama, T. Kanda, M. Kurabayashi, and R. Nagai. 2000. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ. Res. 86:8-14.
3. Aries, A., P. Paradis, C. Lefebvre, R. J. Schwartz, and M. Nemer. 2004. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA 101:6975-6980.
4. Arola, O. J., A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L. M. Voipio-Pulkki. 2000. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 60:1789-1792.
5. Avantaggiati, M. L., M. Carbone, A. Graessmann, Y. Nakatani, B. Howard, and A. S. Levine. 1996. The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J. 15:2236-2248.
6. Bishopric, N. H., P. Andreka, T. Slepak, and K. A. Webster. 2001. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 1:141-150.
7. Bogoyevitch, M. A., J. Gillespie-Brown, A. J. Ketterman, S. J. Fuller, R. Ben-Levy, A. Ashworth, C. J. Marshall, and P. H. Sugden. 1996. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ. Res. 79:162-173.
8. Braz, J. C., O. F. Bueno, Q. Liang, B. J. Wilkins, Y. S. Dai, S. Parsons, J. Braunwart, B. J. Glascock, R. Klevitsky, T. F. Kimball, T. E. Hewett, and J. D. Molkentin. 2003. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J. Clin. Investing. 111:1475-1486.
9. Chakravarti, D., V. Ogryzko, H. Y. Kao, A. Nash, H. Chen, Y. Nakatani, and R. M. Evans. 1999. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393-403.
10. Chan, H. M., and N. B. La Thangue. 2001. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114:2363-2373.
11. Chawla, S., G. E. Hardingham, D. R. Quinn, and H. Bading. 1998. CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. Science 281:1505-1509.
12. Chien, K. R., K. U. Knowlton, H. Zhu, and S. Chien. 1991. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5:3037-3046.
13. Clerk, A., A. Michael, and P. H. Sugden. 1998. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J. Cell Biol. 142:523-535.
14. Communal, C., W. S. Colucci, and K. Singh. 2000. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J. Biol. Chem. 275:19395-19400.
15. Costanzo, A., P. Merlo, N. Pediconi, M. Fulco, V. Sartorelli, P. A. Cole, G. Fontemaggi, M. Fanciulli, L. Schiltz, G. Blandino, C. Balsano, and M. Levrero. 2002. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9:175-186.
16. Cuenda, A., and P. Cohen. 1999. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:4341-4346.
17. Delpy, E., S. N. Hatem, N. Andrieu, C. de Vaumas, M. Henaff, C. Rucker-Martin, J. P. Jaffrezou, G. Laurent, T. Levade, and J. J. Mercadier. 1999. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc. Res. 43:398-407.
18. Eckner, R., J. W. Ludlow, N. L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J. A. DeCaprio, D. M. Livingston, and J. A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16:3454-3464.
19. Giordano, A., and M. L. Avantaggiati. 1999. p300 and CBP: partners for life and death. J. Cell. Physiol. 181:218-230.
20. Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:1553-1577.
21. Grossman, S. R. 2001. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2773-2778.
22. Grossman, S. R., M. Perez, A. L. Kung, M. Joseph, C. Mansur, Z. X. Xiao, S. Kumar, P. M. Howley, and D. M. Livingston. 1998. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2:405-415.
23. Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387:819-823.
24. Gusterson, R. J., E. Jazrawi, I. M. Adcock, and D. S. Latchman. 2003. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J. Biol. Chem. 278:6838-6847.
25. Hamamori, Y., V. Sartorelli, V. Ogryzko, P. L. Puri, H. Y. Wu, J. Y. Wang, Y. Nakatani, and L. Kedes. 1999. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96:405-413.
26. Han, J., Y. Jiang, Z. Li, V. V. Kravchenko, and R. J. Ulevitch. 1997. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296-299.
27. Han, J., J. D. Lee, L. Bibbs, and R. J. Ulevitch. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808-811.
28. Hardingham, G. E., S. Chawla, F. H. Cruzalegui, and H. Bading. 1999. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron 22:789-798.
29. Hu, S. C., J. Chrivia, and A. Ghosh. 1999. Regulation of CBP-mediated transcription by neuronal calcium signaling. Neuron 22:799-808.
30. Huang, S., Y. Jiang, Z. Li, E. Nishida, P. Mathias, S. Lin, R. J. Ulevitch, G. R. Nemerow, and J. Han. 1997. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 6:739-749.
31. Ito, H., S. C. Miller, M. E. Billingham, H. Akimoto, S. V. Torti, R. Wade, R. Gahlmann, G. Lyons, L. Kedes, and F. M. Torti. 1990. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. USA 87:4275-4279.
32. Janknecht, R., and A. Nordheim. 1996. MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem. Biophys. Res. Commun. 228:831-837.
33. Johnson, G. L., and R. Lapadat. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912.
34. Kallunki, T., T. Deng, M. Hibi, and M. Karin. 1996. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87:929-939.
35. Kang, Y. J., Z. X. Zhou, G. W. Wang, A. Buridi, and J. B. Klein. 2000. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275:13690-13698.
36. Kato, Y., V. V. Kravchenko, R. I. Tapping, J. Han, R. J. Ulevitch, and J. D. Lee. 1997. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 16:7054-7066.
37. Kawamura, T., K. Hasegawa, T. Morimoto, E. Iwai-Kanai, S. Miyamoto, Y. Kawase, K. Ono, H. Wada, M. Akao, and T. Kita. 2004. Expression of p300 protects cardiac myocytes from apoptosis in vivo. Biochem. Biophys. Res. Commun. 315:733-738.
38. Kirshenbaum, L. A., and M. D. Schneider. 1995. Adenovirus E1A represses cardiac gene transcription and reactivates DNA synthesis in ventricular myocytes, via alternative pocket protein- and p300-binding domains. J. Biol. Chem. 270:7791-7794.
39. Kitabayashi, I., R. Eckner, Z. Arany, R. Chiu, G. Gachelin, D. M. Livingston, and K. K. Yokoyama. 1995. Phosphorylation of the adenovirus E1A-associated 300 kDa protein in response to retinoic acid and E1A during the differentiation of F9 cells. EMBO J. 14:3496-3509.
40. Kurabayashi, M., S. Dutta, R. Jeyaseelan, and L. Kedes. 1995 Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol. Cell. Biol. 15:6386-6397.
41. Kurabayashi, M., R. Jeyaseelan, and L. Kedes. 1993. Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J. Biol. Chem. 268:5524-5529.
42. Kurabayashi, M., R. Jeyaseelan, and L. Kedes. 1994. Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id gene induction. J. Biol. Chem. 269:6031-6039.
43. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
44. Latella, L., J. Lukas, C. Simone, P. L. Puri, and J. Bartek. 2004. Differentiation-induced radioresistance in muscle cells. Mol. Cell. Biol. 24:6350-6361.
45. Lee, J. C., S. Kumar, D. E. Griswold, D. C. Underwood, B. J. Votta, and J. L. Adams. 2000. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47:185-201.
46. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, and et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
47. Liao, P., D. Georgakopoulos, A. Kovacs, M. Zheng, D. Lerner, H. Pu, J. Saffitz, K. Chien, R. P. Xiao, D. A. Kass, and Y. Wang. 2001. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl. Acad. Sci. USA 98:12283-12288.
48. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827.
49. Liu, Y., and R. N. Kitsis. 1996. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. J. Cell Biol. 133:325-334.
50. Nemoto, S., Z. Sheng, and A. Lin. 1998. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol. Cell. Biol. 18:3518-3526.
51. Ornatsky, O. I., D. M. Cox, P. Tangirala, J. J. Andreucci, Z. A. Quinn, J. L. Wrana, R. Prywes, Y. T. Yu, and J. C. McDermott. 1999. Post-translational control of the MEF2A transcriptional regulatory protein. Nucleic Acids Res. 27:2646-2654.
52. Perkins, N. D. 1997. Achieving transcriptional specificity with NF-kappa B. Int. J. Biochem. Cell Biol. 29:1433-1448.
53. Poizat, C., V. Sartorelli, G. Chung, R. A. Kloner, and L. Kedes. 2000. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol. Cell. Biol. 20:8643-8654.
54. Puri, P. L., and V. Sartorelli. 2000. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J. Cell. Physiol. 185:155-173.
55. Puri, P. L., Z. Wu, P. Zhang, L. D. Wood, K. S. Bhakta, J. Han, J. R. Feramisco, M. Karin, and J. Y. Wang. 2000. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyo-sarcoma cells. Genes Dev. 14:574-584.
56. Raingeaud, J., S. Gupta, J. S. Rogers, M. Dickens, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:7420-7426.
57. Rouaux, C., N. Jokic, C. Mbebi, S. Boutillier, J. P. Loeffler, and A. L. Boutillier. 2003. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22:6537-6549.
58. Shikama, N. W. Lutz, R. Kretzschmar, N. Sauter, J. F. Roth, S. Marino, J. Wittwer, A. Scheidweiler, and R. Eckner. 2003. Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. EMBO J. 22:5175-5185.
59. Snowden, A. W., and N. D. Perkins. 1998. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem. Pharmacol. 55:1947-1954.
60. Sugden, P. H., and A. Clerk. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83:345-352.
61. Sussman, M. A., S. F. Hamm-Alvarez, P. M. Vilalta, S. Welch, and L. Kedes. 1997. Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration. An immunofluorescence microscopy analysis. Circ. Res. 80:52-61.
62. Swope, D. L., C. L. Mueller, and J. C. Chrivia. 1996. CREB-binding protein activates transcription through multiple domains. J. Biol. Chem. 271:28138-28145.
63. Taigen, T., L. J. De Windt, H. W. Lim, and J. D. Molkentin. 2000. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97:1196-1201.
64. Thorburn, J., S. Xu, and A. Thorburn. 1997. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J. 16:1888-1900.
65. Wang, Y., S. Huang, V. P. Sah, J. Ross, Jr., J. H. Brown, J. Han, and K. R. Chien. 1998. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-2168.
66. Wang, Y., B. Su, V. P. Sah, J. H. Brown, J. Han, and K. R. Chien. 1998. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J. Biol. Chem. 273:5423-5426.
67. Wu, Z., P. J. Woodring, K. S. Bhakta, K. Tamura, F. Wen, J. R. Feramisco, M. Karin, J. Y. Wang, and P. L. Puri. 2000. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol. Cell. Biol. 20:3951-3964.
68. Xu, L., R. M. Lavinsky, J. S. Dasen, S. E. Flynn, E. M. McInerney, T. M. Mullen, T. Heinzel, D. Szeto, E. Korzus, R. Kurokawa, A. K. Aggarwal, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1998. Signal-specific co-activator domain requirements for Pit-1 activation. Nature 395:301-306.
69. Yaciuk, P., and E. Moran. 1991. Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol. Cell. Biol. 11:5389-5397.
70. Yanazume, T., K. Hasegawa, T. Morimoto, T. Kawamura, H. Wada, A. Matsumori, Y. Kawase, M. Hirai, and T. Kita. 2003. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23:3593-3606.
71. Yanazume, T., T. Morimoto, H. Wada, T. Kawamura, and K. Hasegawa. 2003. Biological role of p300 in cardiac myocytes. Mol. Cell. Biochem. 248:115-119.
72. Yang, S. H., P. R. Yates, A. J. Whitmarsh, R. J. Davis, and A. D. Sharrocks. 1998. The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol. Cell. Biol. 18:710-720.
73. Yao, T. P., S. P. Oh, M. Fuchs, N. D. Zhou, L. E. Ch'ng, D. Newsome, R. T. Bronson, E. Li, D. M. Livingston, and R. Eckner. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372.
74. Yin, T., G. Sandhu, C. D. Wolfgang, A. Burrier, R. L. Webb, D. F. Rigel, T. Hai, and J. Whelan. 1997. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J. Biol. Chem. 272:19943-19950.
75. Zechner, D., D. J. Thuerauf, D. S. Hanford, P. M. McDonough, and C. C. Glembotski. 1997. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J. Cell. Biol. 139:115-127.
76. Zetser, A., E. Gredinger, and E. Bengal. 1999. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J. Biol. Chem. 274:5193-5200.
77. Zhang, S., C. Weinheimer, M. Courtois, A. Kovacs, C. E. Zhang, A. M. Cheng, Y. Wang, and A. J. Muslin. 2003. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Investig. 111:833-841.